A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Description

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

Conditions

Lymphoma, Non-Hodgkin

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Condition
Lymphoma, Non-Hodgkin
Intervention / Treatment

-

Contacts and Locations

Scottsdale

Mayo Clinic Arizona - Scottsdale, Scottsdale, Arizona, United States, 85259

La Jolla

UCSD Moores Cancer Center, La Jolla, California, United States, 92093

Los Angeles

Local Institution - 114, Los Angeles, California, United States, 90048-1804

Orange

University of California, Irvine, Orange, California, United States, 92848

Whittier

Oncology Institute of Hope and Innovation, Whittier, California, United States, 90603

Jacksonville

Mayo Clinic - Jacksonville, Jacksonville, Florida, United States, 32224

Tampa

H Lee Moffitt Cancer Center, Tampa, Florida, United States, 32207

Overland Park

The University of Kansas - Clinical Research Center, Overland Park, Kansas, United States, 66210

Overland Park

The University of Kansas - Clinical Research Center, Overland Park, Kansas, United States, 66210

Baltimore

University Of Maryland At Baltimore, Baltimore, Maryland, United States, 21201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease
  • * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • * Life expectancy ≤ 2 months
  • * Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter
  • * Is on chronic systemic immunosuppressive therapy or corticosteroids or has clinically significant graft-versus-host disease (GVHD)
  • * Impaired cardiac function or clinically significant cardiac disease

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Celgene,

Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

2027-04-18